Erratum: Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia (Cancer Cell (2011) 19(6) (740–753), (S1535610811001656), (10.1016/j.ccr.2011.05.007));Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia

Cancer Cell

Volumn 19, Issue 6, 2011, Pages 740-753

  Schmidt, Thomas ^a,d   Masouleh, Behzad Kharabi ^a   Loges, Sonja ^a,g   Cauwenberghs, Sandra ^a   Fraisl, Peter ^a   Maes, Christa ^a   Jonckx, Bart ^a   De Keersmaecker, Kim ^a,b   Kleppe, Maria ^a   Tjwa, Marc ^a   Schenk, Thomas ^c,d   Vinckier, Stefan ^a   Fragoso, Rita ^e   De Mol, Maria ^a   Beel, Karolien ^a   Dias, Sérgio ^e   Verfaillie, Catherine ^a   Clark, Richard E ^f   Brümmendorf, Tim H ^g,h   Vandenberghe, Peter ^a   Rafii, Shahin ⁱ   Holyoake, Tessa ^j   Hochhaus, Andreas ^c,d   Cools, Jan ^a,b   Karin, Michael ^k   Carmeliet, Geert ^a   Dewerchin, Mieke ^a   Carmeliet, Peter ^a   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k San Diego   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5D11D4; ANTINEOPLASTIC AGENT; BCR ABL1 PROTEIN; IMATINIB; ONCOPROTEIN; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION;

MUS;

EID: 79958732559     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2019.12.010     Document Type: Erratum

References (44)

1. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., Koller C., Estrov Z., O'Brien S., Keating M., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
2. Arroyo J., Torry R.J., Torry D.S. Deferential regulation of placenta growth factor (PlGF)-mediated signal transduction in human primary term trophoblast and endothelial cells. Placenta 2004, 25:379-386.
3. Bartoli M., Gu X., Tsai N.T., Venema R.C., Brooks S.E., Marrero M.B., Caldwell R.B. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J. Biol. Chem. 2000, 275:33189-33192.
4. Bellik L., Vinci M.C., Filippi S., Ledda F., Parenti A. Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. Br. J. Pharmacol. 2005, 146:568-575.
5. Buesche G., Ganser A., Schlegelberger B., von Neuhoff N., Gadzicki D., Hecker H., Bock O., Frye B., Kreipe H. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007, 21:2420-2427.
6. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
7. Coenegrachts L., Maes C., Torrekens S., Van Looveren R., Mazzone M., Guise T.A., Bouillon R., Stassen J.M., Carmeliet P., Carmeliet G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res. 2010, 70:6537-6547.
8. Cramer M., Nagy I., Murphy B.J., Gassmann M., Hottiger M.O., Georgiev O., Schaffner W. NF-kappaB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol. Chem. 2005, 386:865-872.
9. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
10. De Keersmaecker K. ABL1 fusions in T-cell acute lymphoblastic leukemia. Verh. K. Acad. Geneeskd. Belg. 2008, 70:245-255.
11. Ding W., Knox T.R., Tschumper R.C., Wu W., Schwager S.M., Boysen J.C., Jelinek D.F., Kay N.E. Platelet derived growth factor (PDGF) - PDGF receptor interaction activates bone marrow derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116:2984-2993.
12. Ding Y., Huang Y., Song N., Gao X., Yuan S., Wang X., Cai H., Fu Y., Luo Y. NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha. J. Immunol. 2010, 184:2593-2601.
13. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
14. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
15. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
16. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
17. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
18. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
19. Fragoso R., Pereira T., Wu Y., Zhu Z., Cabecadas J., Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006, 107:1608-1616.
20. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., Hicklin D.J., Zhu Z., Bohlen P., Witte L., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 2002, 8:841-849.
21. Hazlehurst L.A., Bewry N.N., Nair R.R., Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Contr. 2009, 16:100-107.
22. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 1998, 95:9349-9354.
23. Konopleva M., Tabe Y., Zeng Z., Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 2009, 12:103-113.
24. Korkolopoulou P., Viniou N., Kavantzas N., Patsouris E., Thymara I., Pavlopoulos P.M., Terpos E., Stamatopoulos K., Plata E., Anargyrou K., et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003, 17:89-97.
25. Landgren E., Schiller P., Cao Y., Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 1998, 16:359-367.
26. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114:1150-1157.
27. Li W.W., Hutnik M., Gehr G. Antiangiogenesis in haematological malignancies. Br. J. Haematol. 2008, 143:622-631.
28. Maffei R., Martinelli S., Castelli I., Santachiara R., Zucchini P., Fontana M., Fiorcari S., Bonacorsi G., Ilariucci F., Torelli G., Marasca R. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk. Res. 2009, 34:312-321.
29. Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., Legros L., Charbonnier A., Guerci A., Varet B., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035.
30. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., Akiyama T., Kuroda H., Kawano Y., Kobune M., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 2003, 9:1158-1165.
31. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002, 100:3767-3775.
32. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
33. Nair R.R., Tolentino J., Hazlehurst L.A. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem. Pharmacol. 2010, 80:602-612.
34. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
35. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., Baik G.H., Shibata W., Diprete B., Betz K.S., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272.
36. Quintas-Cardama A., Kantarjian H., Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009, 6:535-543.
37. Rajan S., Ye J., Bai S., Huang F., Guo Y.L. NF-kappaB, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells. J. Cell. Biochem. 2008, 105:477-486.
38. Taylor A.P., Leon E., Goldenberg D.M. Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Br. J. Cancer 2010, 103:82-89.
39. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
40. Van Etten R.A. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk. Res. 2004, 28(Suppl 1):S21-S28.
41. Zahiragic L., Schliemann C., Bieker R., Thoennissen N.H., Burow K., Kramer C., Zuhlsdorf M., Berdel W.E., Mesters R.M. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007, 21:1310-1312.
42. Zetterberg E., Lundberg L.G., Palmblad J. Characterization of blood vessels in bone marrow from patients with chronic myeloid leukemia and polycythemia vera. Scand. J. Clin. Lab. Invest. 2004, 64:641-647.
43. Zhao F., Mancuso A., Bui T.V., Tong X., Gruber J.J., Swider C.R., Sanchez P.V., Lum J.J., Sayed N., Melo J.V., et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010, 29:2962-2972.
44. Zohlnhofer D., Brand K., Schipek K., Pogatsa-Murray G., Schomig A., Neumann F.J. Adhesion of monocyte very late antigen-4 to endothelial vascular cell adhesion molecule-1 induces interleukin-1beta-dependent expression of interleukin-6 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20:353-359.